Skip to content

Gross Profit at other companies

AbbVie logo
AbbVieABBV
$10.78B+15.4%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$9.46M+0.2%
Warby Parker logo
Warby ParkerWRBY
$131.04M+4.0%
Glaukos logo
GlaukosGKOS
$117.23M+42.4%

Other financials

Income statement

See full
Revenue$162.1M+107%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Calculated from Tarsus Pharmaceuticals, Inc.’s reported figures.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s gross profit?
Tarsus Pharmaceuticals, Inc. (TARS) reported gross profit of $152.66M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s gross profit changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s gross profit increased by 108.8% year-over-year, from $73.12M to $152.66M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.